Conceptio
›
car-t-cells
Topic
car-t-cells
Knowledge-graph topic
· documents ABOUT car-t-cells across the archive
32
Documents about car-t-cells
Documents about car-t-cells
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
#801882
ClinicalTrials.gov
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
#883085
ClinicalTrials.gov
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
#801446
ClinicalTrials.gov
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
#901469
ClinicalTrials.gov
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
#851126
ClinicalTrials.gov
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
#861685
ClinicalTrials.gov
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
#230466
ClinicalTrials.gov
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
#833406
ClinicalTrials.gov
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
#1047582
ClinicalTrials.gov
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
#884687
ClinicalTrials.gov
Additional file 1 of Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis
#296753
Figshare
Additional file 3 of Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood
#377658
Figshare
Additional file 2 of Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood
#377659
Figshare
Additional file 1 of Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood
#377660
Figshare
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
#628547
ClinicalTrials.gov
Harnessing the therapeutic potential of umbilical cord blood and pediatric thymus for the development of allogeneic off-the-shelf CAR regulatory T Cells / Samikshya Santosh Nirmala ; Gutachter: Anke Fuchs, Achim Temme
#669383
Deutsche Nationalbibliothek
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia
#886802
ClinicalTrials.gov
Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.
#899482
ClinicalTrials.gov
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
#141101
ClinicalTrials.gov
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
#253083
ClinicalTrials.gov
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia
#895135
ClinicalTrials.gov
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
#279509
ClinicalTrials.gov
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
#467597
ClinicalTrials.gov
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
#810294
ClinicalTrials.gov
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
#838479
ClinicalTrials.gov
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
#349945
ClinicalTrials.gov
A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
#435746
ClinicalTrials.gov
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
#609399
eScholarship
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
#898600
ClinicalTrials.gov
Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.
#800627
ClinicalTrials.gov
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
#28336
ClinicalTrials.gov
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
#217035
ClinicalTrials.gov
Dual targeting of solid tumors using cytokine-induced killer cells modified with a CAR anti-tenascin C and a secretable EGFRxCD3 bispecific antibody
#202774
IRIS
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
#860629
ClinicalTrials.gov
This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.
#67863
ClinicalTrials.gov
A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.
#831884
ClinicalTrials.gov
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
#992861
ClinicalTrials.gov
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
#492031
eScholarship
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
#893275
ClinicalTrials.gov
← Previous
Page 6 of 6
Topic record
· derived from the Conceptio knowledge graph (shared subject terms across the corpus)
Conceptio Open Knowledge Archive — topic hubs link to canonical document pages with full provenance.